STOCK TITAN

Viridian Therapeutics, Inc.\DE (VRDN) SEC Filings

VRDN NASDAQ
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) ownership disclosures report 8,257,672 common shares, or 7.3%, beneficially owned by Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D., as of September 30, 2026. The Adviser, its general partner and Senai Asefaw may be deemed beneficial owners of shares directly held by Paradigm BioCapital International Fund Ltd. and one or more separately managed accounts.

The Fund separately reported beneficial ownership of 7,278,105 shares, or 6.4%. The percentages are based on 113,292,269 shares outstanding as of August 3, 2026. The reporting persons’ figures overlap and should not be added together.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
ownership
-
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) common stock was the subject of an amended Schedule 13G in which T. Rowe Price Associates, Inc. reported beneficial ownership of 5,123,592 shares, or 4.5%, as of September 30, 2026. The report lists sole voting power over 5,123,546 shares and sole dispositive power over 5,123,592 shares, with no shared voting or dispositive power. T. Rowe Price Associates, Inc. expressly denied that the filing constituted an admission of beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
ownership
-
Rhea-AI Summary

VRDN reported that State Street Corporation beneficially owned 4,876,395 common shares, representing 4.3% of the class, as of September 30, 2026. State Street reported shared voting power over 4,633,744 shares and shared dispositive power over 4,876,395 shares. It reported zero sole voting power and zero sole dispositive power, and the position was classified as ownership of 5 percent or less of the class.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
ownership
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) reported Phase 1 results for VRDN-008, a half-life-extended FcRn inhibitor, in six healthy volunteers. Subcutaneous dosing showed IgG reduction through 8 weeks, reaching 74% at peak. VRDN-008 had a half-life of 15 to 18 days, five to six times longer than first-generation Fc fragments; it spared albumin and low-density lipoprotein and was generally well tolerated.

Pharmacokinetic modeling supports advancing every-eight-week and every-four-week dosing regimens into registrational development. Viridian plans at least one pivotal trial in 2027, starting with myasthenia gravis in mid-2027, pending regulatory feedback. The planned multi-arm MG trial will test Q4W and Q8W dosing versus placebo using the enFuse device. Viridian plans to focus its FcRn development efforts on VRDN-008 and may pursue VRDN-006 in the future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
current report
-
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) reported $25.752 million in revenue for the three months ended September 30, 2026, including $24.671 million from veligrotug, which received FDA approval in June. Revenue was $70.570 million a year earlier, including $70.000 million in license revenue. Net loss was $101.209 million versus $34.599 million; for the nine months, net loss was $333.229 million versus $222.246 million.

As of September 30, cash, cash equivalents and marketable securities totaled $955.2 million. Viridian said these resources were expected to fund planned operations for at least twelve months from issuance. Net cash used in operating activities was $317.751 million for nine months, compared with $252.637 million in 2025. Viridian issued $250.0 million of 1.75% convertible senior notes due 2032 and paid Hercules $55.1 million to terminate its loan facility, recording a $4.1 million debt-extinguishment loss. Following FDA approval, it received a $75.0 million milestone payment from DRI; the future-revenue liability was $121.608 million at September 30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.53%
Tags
quarterly report
-
Rhea-AI Summary

Viridian Therapeutics, Inc. reported third-quarter 2026 total revenue of $25.752 million, including $24.7 million in Lumvoa net product revenue, with more than 100 patients on therapy at quarter-end. Total revenue was $70.570 million in Q3 2025, when license revenue was $70.000 million. Net loss was $101.209 million, compared with $34.599 million a year earlier.

Cash, cash equivalents and marketable securities totaled $955.206 million as of September 30, 2026, compared with $874.652 million at December 31, 2025. Quarterly research and development expense was $70.093 million versus $86.261 million; selling, general and administrative expense was $57.609 million versus $24.322 million.

Viridian said the elegrobart Biologics License Application for thyroid eye disease is on track for Q1 2027, and VRDN-008 Phase 1 data disclosure is on track for Q4 2026. It expects to initiate a Phase 1 trial of VRDN-292 in patients in Q4 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.53%
Tags
current report
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) reported that Chief Legal Officer Jennifer Tousignant exercised stock options and sold shares on August 19, 2026. She exercised options to acquire 10,000 shares of common stock at $14.41 per share, then sold a total of 14,212 shares of common stock at $24.50 per share in open-market or private transactions, including 718 shares previously acquired under the company’s Employee Stock Purchase Plan. Following the option exercise, 114,072 option shares remain outstanding under the reported grant, which was issued on March 3, 2025 and vests in 48 equal monthly installments through March 3, 2029, with an expiration date of March 3, 2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
insider
-
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) is reported to have 5,687,507 shares of its common stock beneficially owned, representing 5.0% of the class, by a group led by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as of August 19, 2026.

The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. The reporting persons have shared voting and dispositive power over these 5,687,507 shares and no sole voting or dispositive power. They state that the filing should not be construed as an admission of beneficial ownership under Section 13 of the Exchange Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
ownership
-
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) is the issuer of common stock that an officer, Jennifer Tousignant, has notified an intention to sell under Rule 144. The notice covers 14,212 shares of common stock, with an aggregate market value of $348,194.00, and lists 113,292,269 shares outstanding. The planned sales, through Fidelity Brokerage Services LLC on NASDAQ around August 19, 2026, are sourced from restricted stock vesting, an ESPP purchase, and a stock option exercise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
other
Rhea-AI Summary

Viridian Therapeutics, Inc. (VRDN) reported that its Chief Medical Officer, Radhika Tripuraneni, exercised a stock option for 40,000 shares of common stock on 2026-08-14 at an exercise price of $13.21 per share. The exercised option, which was fully vested, now shows 0 derivative shares remaining, and her directly held common stock position increased to 40,000 shares following the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
insider

FAQ

How many Viridian Therapeutics, Inc.\\DE (VRDN) SEC filings are available on StockTitan?

StockTitan tracks 83 SEC filings for Viridian Therapeutics, Inc.\\DE (VRDN), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Viridian Therapeutics, Inc.\\DE (VRDN)?

The most recent SEC filing for Viridian Therapeutics, Inc.\\DE (VRDN) was filed on November 16, 2026.